Announcements Trials
Browse Landscape

Phase

Phase NA 8Phase 1 3Phase EARLY_PHASE1 2Phase 3 2Phase 2 2Phase 4 1Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 1Endocrine 1Breast 1

Conditions

Neoplasms 2009Carcinoma, Non-Small-Cell Lung 1222Breast Neoplasms 1214Leukemia, Myeloid, Acute 965Neoplasm Metastasis 900Melanoma 777Colorectal Neoplasms 749Lymphoma 725Multiple Myeloma 723Ovarian Neoplasms 673Pancreatic Neoplasms 664Prostatic Neoplasms 657Lymphoma, Non-Hodgkin 657Recurrence 636Precursor Cell Lymphoblastic Leukemia-Lymphoma 583Lung Neoplasms 559Leukemia, Lymphocytic, Chronic, B-Cell 555Glioblastoma 527Leukemia 485Lymphoma, Large B-Cell, Diffuse 440Lymphoma, Follicular 418Brain Neoplasms 413Squamous Cell Carcinoma of Head and Neck 388Stomach Neoplasms 386Carcinoma, Renal Cell 384Myelodysplastic Syndromes 381Carcinoma, Hepatocellular 367Advanced Solid Tumors 356Lymphoma, Mantle-Cell 345Glioma 342

Interventions

volagidemab 2relacorilant 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Hyperglycemia × Clear all
NCT04373265 2024-02-23

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

Corcept Therapeutics

Phase 1 Completed
15 enrolled
Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Adrenal Gland Diseases, Adrenocortical Hyperfunction, Cushing Syndrome, Diabetes Mellitus, Type 2, Endocrine System Diseases, Hyperglycemia, Hypertension, Pathologic Processes, Glucose Intolerance, Adrenocortical Carcinoma

NCT04330625 2022-11-08

Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)

Duke University

Phase 1 Terminated
1 enrolled
Breast

Breast Neoplasms, Hyperglycemia, Hereditary Sensory and Autonomic Neuropathies

NCT04253223 2021-06-11

A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib

Duke University

Phase 1 Terminated
1 enrolled
Lymphoid

Hyperglycemia, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡